The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 944 African-American and Caucasian men and women. Plasma lipid and lipoprotein were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations to baseline measurements and changes in response to simvastatin treatment.

Whole genome genotyping was performed on 592 Caucasians CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 subjects were genotyped, which included 280 subjects genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies.

The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 944 African-American and Caucasian men and women. Plasma lipid and lipoprotein were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations to baseline measurements and changes in response to simvastatin treatment.

Whole genome genotyping was performed on 592 Caucasians CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 subjects were genotyped, which included 280 subjects genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies.